Sun Pharma has alerted its distribution partners about the growing threat of counterfeit medicines

Major pharmaceutical companies in India are cautioning their distribution partners about the growing issue of counterfeit medicines, particularly in West Bengal. Sun Pharma, the country’s largest drug manufacturer, issued an advisory on March 18 urging its CFAs and distributors to purchase only from authorized sources to prevent counterfeit and substandard drugs from entering the supply chain.

The company warned that buying from unauthorized sources could compromise patient safety and called for full cooperation from distributors and retailers. It also discouraged semi-wholesale trading, bartering, and undercutting, which could facilitate counterfeit infiltration.

Sun Pharma urged its partners to educate chemists about fake drugs and avoid suppliers offering excessive discounts. Additionally, distributors were asked to report any suspicious activities, such as unusually high orders or unethical business practices.

With rising counterfeit cases, drug regulators are monitoring potential black-market activities, reinforcing concerns across the pharmaceutical industry.

31-03-2025